Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2021;9(22):11 Osteoarthritis and Cartilage. 2011 Oct 1;19(10):1169-75.What this means for my practice?
Repeated injections of IA-BioHA appear to be safe and effective in treating painful knee OA.
Study Summary
Four hundred and thirty-three patients who had knee osteoarthritis (OA) entered a multicenter open-label stage of the FLEXX trial. All the patients received one injection of 2 mL IA-BioHA (a non-cross-linked, high molecular weight hyaluronan) per week for 3 weeks. About 43% of the patients reported any adverse events (AEs). Less than 5% had treatment-related AEs. Symptom improvement was maintained. The results revealed that repeated injections of IA-BioHA were safe and effective in treating knee OA.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
